glycolipid/悪性腫瘍

FIELD OF THE INVENTION The present invention relates to the use of .alpha.-C-galactosyl ceramides (.alpha.-C-GalCer) synthetic glycolipids as adjuvants to augment the immunogenicity of various infectious and tumor antigens. BACKGROUND OF THE INVENTION The successful elimination of pathogens,

CROSS-REFERENCE TO RELATED APPLICATIONS This patent application is related to co-pending U.S. patent application Ser. No. 12/485,546, titled "Compositions for inducing immune responses specific to Globo H and SSEA-3 and uses thereof in cancer treatment" filed Jun. 16, 2009, which claims priority to

FIELD OF THE INVENTION The invention is directed to novel synthetic C-glycolipids, which are useful in treating cancer, infectious diseases and autoimmune diseases. Specifically, the invention is directed to novel synthetic analogs of .alpha.-C-galactosylceramides, which are potent mediators of

FIELD OF THE INVENTION The invention is directed to novel synthetic C-glycolipids, which are useful in treating cancer, infectious diseases and autoimmune diseases. Specifically, the invention is directed to novel synthetic analogs of .alpha.-C-galactosylceramides, which are potent mediators of

FIELD OF THE INVENTION The invention relates to pharmaceutical compositions comprising the .alpha.-Gal glycolipid (9Z,9'Z)-(2R)-3-(((2-(6-((3-(((2R,3R,4R,5S,6R)-3-acetamido-5-(((2S,3R,4S,- 5S,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(((2R,3R,4S,5R,6R)-3,4,5-trihydro-

TECHNICAL FIELD OF THE INVENTION This invention relates to the field of cancer vaccines. In particular, the application relates to a carbohydrate-based vaccine containing the B cell epitope, Globo H, which is conjugated to the immunogenic carrier DT-CRM197. More particularly, the invention is

TECHNICAL FIELD OF THE INVENTION This invention relates to the field of cancer vaccines. In particular, the application relates to a carbohydrate-based vaccine containing the B cell epitope, Globo H, which is conjugated to the immunogenic carrier DT-CRM197. More particularly, the invention is

BACKGROUND OF THE INVENTION Tumor-specific antigens have been identified and pursued as targets for vaccines. Previous work from the inventors' has shown that monovalent vaccines utilizing the tumor antigens Globo H, Lewis.sup.y, GM2, glycosylated MUC-1, Tn(c), sTn(c), or TF(c) conjugated to KLH to

Throughout this application, various references are referred to. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. BACKGROUND OF THE INVENTION Tumor-specific

BACKGROUND OF THE INVENTION Tumor-specific antigens have been identified and pursued as targets for vaccines. Previous work from the inventors' has shown that monovalent vaccines utilizing the tumor antigens Globo H, Lewis.sup.y, GM2, glycosylated MUC-1, Tn(c), sTn(c), or TF(c) conjugated to KLH to

Throughout this application, various references are referred to. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. BACKGROUND OF THE INVENTION Tumor-specific

Throughout this application, various references are referred to. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. BACKGROUND OF THE INVENTION Tumor-specific

INTRODUCTION The CD1d molecule is a member of the CD1 family of .beta.2 microglobulin-associated molecules. In contrast to class I and II major histocompatibility complex (MHC) molecules that present protein antigens to CD8+ and CD4+ T cells, respectively, CD1 molecules have evolved to capture and

FIELD OF THE PRESENT INVENTION The present invention relates to adjuvants of the glycolipid type and their uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new uses of compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in

FIELD OF THE INVENTION The present invention is directed to novel synthetic C-glycolipids that selectively induce a Th1-type immune response characterized by enhanced IL-12 secretion and increased activation of antigen-presenting cells (APCs) such as dendritic cells, and are useful in treating